Archive · 12 Nov 2025
Zydus Lifesciences Enters China Market with Antidepressant Approval
A company called Zydus Lifesciences, which makes medicines in India, has just gotten permission to sell one of its important medicines in China.
This medicine is called Venlafaxine and it helps people who feel very sad or worried.
It's like giving a little boost to the brain's happy chemicals.
Zydus will make these pills in India and then sell them in China.
China is a big country with lots of people, and they have a growing need for medicines that help with mental health.
This is Zydus's first time selling medicine in China, and they hope it will help many people there feel better.
They plan to work with other companies in China to make sure the medicine gets to everyone who needs it.
Zydus Lifesciences has obtained its first Chinese market approval for Venlafaxine Extended-Release (ER) capsules.
The approval marks Zydus's debut in the Chinese pharmaceutical market, expanding its global presence.
Venlafaxine ER capsules are used to treat major depressive, generalized anxiety, social anxiety, and panic disorders.
The Chinese market for Venlafaxine was valued at approximately $45.2 million in 2020 and is projected to grow significantly by 2025.
Zydus plans to utilize strategic partnerships and local collaborations for efficient commercialization in China.
- Who
- Zydus Lifesciences
- What
- Received first-ever Chinese market approval for its Venlafaxine ER capsules.
- When
- The approval was announced recently, marking the company's entry into the Chinese market.
- Where
- China
- Why
- To expand its global footprint in regulated international markets and to address the growing mental health needs in China.
- Product
- Venlafaxine Extended-Release (ER) capsules (75 mg and 150 mg)
- Regulatory Body
- China's National Medical Products Administration (NMPA)
- Manufacturing Facility
- Moraiya, near Ahmedabad, India
- China Venlafaxine Market Value (2020)
- CNY 294 million (approx. $45.2 million)
- China Venlafaxine Market Projection (2025)
- CNY 473.63 million (approx. $66.52 million)
- Market Growth Rate (CAGR)
- 8.8 percent